Endothelin-1 indicates unfavorable prognosis in primary high-grade non-muscle-invasive urothelial bladder cancer
https://doi.org/10.4081/aiua.2021.2.143
Accepted: January 23, 2021
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Objective: To conduct a prospective study of the potential prognostic role of endothelin-1 (ET-1) in a cohort of primary high-grade non-muscle-invasive urothelial bladder cancer patients, who were treated with adjuvant intravesical Bacillus Calmette-Guérin (BCG).
Material and methods: Patients with primary high-grade nonmuscle- invasive urothelial bladder cancer, who received postoperatively induction and maintenance BCG therapy, were prospectively included. Recurrence and progression were histologically proven. Immunohistochemical staining for ET-1 was assessed. Epidemiological, pathological and clinical parameters as well as the expression of ET-1 in tumor specimens were statistically analyzed for recurrence, progression, recurrence-free survival (RFS) and progression-free survival (PFS).
Results: ET-1 associates significantly with recurrence (p = 0.000), progression (p = 0.000), RFS (p = 0.000) and PFS (p = 0.000). The patient’s age is also significant for recurrence (p = 0.003, OR = 1.273 95% CI: 1.086-1.492) and RFS (p = 0.013).
Conclusions: ET-1 seems to deteriorate prognosis in patients suffering from primary high-grade non-muscle-invasive urothelial bladder cancer, who are treated with adjuvant BCG instillations. Furthermore, the patient’s age associates with an increased likelihood for recurrence.
Sylvester RJ, Brausi MA, Kirkels WJ, et al. Long-term efficacy results of EORTC Genito-Urinary Group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guérin, and bacillus Calmette-Guérin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder. Eur Urol. 2010; 57:766-773. DOI: https://doi.org/10.1016/j.eururo.2009.12.024
Soloway M, Khoury S. Bladder Cancer. 2nd Edition: ICUD-EAU 2012; 254-261.
Cambier S, Sylvester RJ, Collette L, et al. EORTC nomograms and risk groups for predicting recurrence, progression, and diseasespecific and overall survival in non-muscle-invasive stage Ta-T1 urothelial bladder cancer patients treated with 1-3 years of maintenance Bacillus Calmette-Guérin. Eur Urol. 2016; 69:60-9. DOI: https://doi.org/10.1016/j.eururo.2016.01.055
Mitrakas L, Gravas S, Papandreou C, et al. Primary high-grade non-muscle-invasive bladder cancer: high NF-B expression in tumor specimens distinguishes patients who are at risk for disease progression. Pathol Oncol Res. 2019; 25:225-231. DOI: https://doi.org/10.1007/s12253-017-0340-1
Mitrakas L, Gravas S, Karasavvidou F, et al. Endothelin-1 overexpression: a potential biomarker of unfavorable prognosis in nonmetastatic muscle-invasive bladder cancer. Tumour Biol. 2015; 36:4699-705. Erratum in: Tumour Biol. 2015; 36:3127 DOI: https://doi.org/10.1007/s13277-015-3118-7
Lamm DL, Blumenstein BA, Crissman JD, et al. Maintenance bacillus Calmette-Guérin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol. 2000; 163:1124-1129. DOI: https://doi.org/10.1016/S0022-5347(05)67707-5
Babjuk M, Böhle A, Burger M, et al. EAU Guidelines on non-muscle- invasive urothelial carcinoma of the bladder: update 2016. Eur Urol. 2017; 71:447-461. DOI: https://doi.org/10.1016/j.eururo.2016.05.041
Zachos I, Tzortzis V, Mitrakas L, et al. Tumor size and T stage correlate independently with recurrence and progression in high-risk non-muscle-invasive bladder cancer patients treated with adjuvant BCG. Tumour Biol. 2014; 35:4185-4189. DOI: https://doi.org/10.1007/s13277-013-1547-8
Sylvester RJ, van der Meijden AP, Oosterlinck W, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol. 2006; 49:466-5. DOI: https://doi.org/10.1016/j.eururo.2005.12.031
Palou J, Sylvester RJ, Faba OR, et al. Female gender and carcinoma in situ in the prostatic urethra are prognostic factors for recurrence, progression, and disease-specific mortality in T1G3 bladder cancer patients treated with bacillus Calmette-Guérin. Eur Urol. 2012; 62:118-25. DOI: https://doi.org/10.1016/j.eururo.2011.10.029
Gontero P, Sylvester R, Pisano F, et al. Prognostic factors and risk groups in T1G3 non-muscle-invasive bladder cancer patients initially treated with Bacillus Calmette-Guérin: results of a retrospective multicenter study of 2451 patients. Eur Urol. 2015; 67:74-82. DOI: https://doi.org/10.1016/j.eururo.2014.08.062
Sahan A, Gerin F, Garayev A, et al. The impact of tumor invasion to muscularis mucosaevascular plexus on patient outcome in pT1 bladder urothelial carcinoma. Arch Ital Urol Androl. 2020; 92:239-243. DOI: https://doi.org/10.4081/aiua.2020.3.239
Eltze E, Wild PJ, Wülfing C, et al. Expression of the endothelin axis in noninvasive and superficially invasive bladder cancer. Relation to clinicopathologic and molecular prognostic parameters. Eur Urol. 2009; 56:837-847. DOI: https://doi.org/10.1016/j.eururo.2008.10.003
Wülfing C, Eltze E, Yamini J, et al. Expression of the endothelin axis in bladder cancer: Relationship to clinicopathologic parameters and long-term survival. Eur Urol. 2005; 47:593-600. DOI: https://doi.org/10.1016/j.eururo.2004.12.019
Wülfing C, Tiemann A, Persigehl T, et al. In vivo activity of ABT- 627, a selective endothelin-A-receptor antagonist, in bladder cancer xenograft tumors. Proc Am Soc Cancer Res. 2005; 46:abstract 3039.
Herrmann E, Tiemann A, Eltze E, et al. Endothelin-A-receptor antagonism with atrasentan exhibits limited activity on the KU-19-19 bladder cancer cell line in a mouse model. J Cancer Res Clin Oncol. 2009; 135:1455-1462. DOI: https://doi.org/10.1007/s00432-009-0593-5
Herrmann E, Bögemann M, Bierer S, et al. The role of the endothelin axis and microvessel density in bladder cancer - correlation with tumor angiogenesis and clinical prognosis. Oncol Rep. 2007; 18:133-138. DOI: https://doi.org/10.3892/or.18.1.133
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
Downloads
Citations
